FindTrial
Sign In

Efficacy of telemedicine based on WeChat platform for lung cancer immunotherapy patients

Efficacy of telemedicine based on WeChat platform for lung cancer immunotherapy patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061119
Enrollment
Unknown
Registered
2022-06-15
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

Intervention group:telemedicine group
Control group:routine education guidance

Sponsors

Shanghai Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18; 2. Follow the NSCLC diagnosis and treatment standards (2018 edition); 3. Patients with NSCLC clinical-stage IIIB or IV; 4. Willing to accept immunotherapy; 5. Patients and their family members can use smartphones and have access to the Internet; 6. ECOG score is 02; 7. Expected survival time >= 6 months.

Exclusion criteria

Exclusion criteria: 1. Patients with mental and cognitive impairment; 2. Patients with difficulties in language expression and communication; 3. Patients with severe liver and kidney function impairment and other malignant tumors.

Design outcomes

Primary

MeasureTime frame
Self-efficacy;immune-related adverse events;—

Secondary

MeasureTime frame
Quality of life;—

Countries

China

Contacts

Public ContactMing Zhang
gason2000@126.com+86 18017320233

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026